Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
96.41 CHF | +1.01% | -39.82% | -47.70% |
Jul. 15 | Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing | MT |
Jul. 12 | China approves CSPC Pharma's RSV vaccine for clinical trials | RE |
Sales 2024 * | 4.15B 3.71B | Sales 2025 * | 4.81B 4.3B | Capitalization | 46.56B 41.63B |
---|---|---|---|---|---|
Net income 2024 * | -2.7B -2.41B | Net income 2025 * | -2.05B -1.84B | EV / Sales 2024 * | 9.7 x |
Net cash position 2024 * | 6.25B 5.59B | Net cash position 2025 * | 4.17B 3.73B | EV / Sales 2025 * | 8.81 x |
P/E ratio 2024 * |
-17.9
x | P/E ratio 2025 * |
-23.8
x | Employees | 5,600 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.44% |
Latest transcript on Moderna, Inc.
1 day | +1.01% | ||
Current month | -47.70% | ||
Current year | -47.70% |
Managers | Title | Age | Since |
---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 51 | 11-02-28 |
James Mock
DFI | Director of Finance/CFO | 47 | 22-09-05 |
Stephen Hoge
PSD | President | 48 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 65 | 18-05-31 |
Director/Board Member | 74 | 20-06-30 | |
Francois Nader
BRD | Director/Board Member | 67 | 19-12-10 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B | |
-3.85% | 11.14B |
- Stock Market
- Equities
- MRNA Stock
- 0QF Stock